FT576 results were very underwhelming. anti-BCMA. The number of edits goes up with anticipated improvements in ORR that are not happening in clinics. FATE's iPSC approach led the NK excitement back in late 2020 and it seems iPSC is not delivering. MDACC's cbNK process seems to deliver. Scalability is the question mark.
Market Data 
Markets 
